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transformed values) in each medium, the magnitude of
increase in MIC or MBC, and the ratios of MBC to MIC for
each drug in MHB-S and MHB-S/HS were compared with
data obtained in MHB by using the Wilcoxon signed-rank
test for matched pairs. Differences were considered significant at the P < 0.05 level for a two-tailed test.
The activities of ciprofloxacin and enoxacin against nine
strains of P. aeruginosa in the four media tested are summarized in Table 1. Cation supplementation of MHB with or
without human serum significantly reduced the activities of
both drugs (P < 0.01). MICs and MBCs showed a median
two- to fourfold increase at both inoculum sizes tested. The
magnitudes of reduction of activity in supplemented broth
were similar for ciprofloxacin and enoxacin (P > 0.05). The
median MICs obtained by the agar dilution technique were
two times higher than in MHB for ciprofloxacin (P < 0.05),
whereas no significant difference was found with enoxacin
(Table 1).
Both quinolones were highly active against non-Pseudomonas strains, with all strains inhibited by 1 ,ug of
ciprofloxacin and 2 ,ug of enoxacin per ml. The results
obtained with the laboratory reference strains when tested
with the larger inocula are presented in Table 2. Compared
with P. aeruginosa, the effect of cation supplementation on
the activities of the quinolones was quantitatively less pronounced and less consistent among the nine strains of E.
coli, K. pneumoniae, and S. aureus. With the three strains of
E. coli tested, the MICs determined the MHB-S were
consistently two times higher than in unsupplemented MHB
for both drugs and both inoculum sizes; however, this
increase was not observed in the presence of serum. The
activities of the quinolones against K. pneumoniae and S.
aureus were not substantially affected by cation supplementation. Compared with the respective median MICs and
MBCs determined in MHB, there was either no change or
only a twofold change in MHB-S, MHB-S/HS, or MHA.
Both drugs appeared to be bactericidal against all bacteria
in the three liquid media; on the average, the MBC was only
one twofold dilution (range, 0 to 4) higher than the MIC.
There was no effect of media on the ratio of MBC to MIC for
ciprofloxacin or enoxacin (P > 0.05).
The activities of ciprofloxacin and enoxacin against all
species were not substantially influenced by a 100-fold
increase in inoculum size (Table 1). The median MIC (or

Several new fluorinated piperazinyl quinolone compounds
have been shown to have potent antibacterial effects, most
notably against gram-negative bacilli (7). However, available
pharmacokinetic and microbiological data suggest that the
differences between achievable serum or tissue concentrations in vivo and inhibitory or bactericidal concentrations for
certain pathogens (e.g., Pseudomonas aeruginosa) may be
small. Therefore, relatively small changes in activity found
in tests performed by standardized methods in media that
more accurately reflect in vivo conditions could be important. The objective of this study was to evaluate the in vitro
activities of two new quinolone agents, ciprofloxacin (Miles
Pharmaceuticals, West Haven, Conn.) and enoxacin
(Warner-Lambert Pharmaceuticals, Ann Arbor, Mich.) in
four different media using standardized susceptibility-testing
methods.
Broth dilution studies were conducted by the microtechnique with two inoculum sizes (8, 11). Three liquid
media were used: Mueller-Hinton broth (MHB; Difco Laboratories, Detroit, Mich.), MHB supplemented with calcium
(2.5 mM/liter) and magnesium (1.1 mM/liter) (MHB-S), and
MHB-S combined 1:1 with fresh heat-inactivated human
serum (MHB-S/HS) (18). The MBC was read as the lowest
concentration of drug that resulted in 99.9% reduction of the
initial inoculum size after transfer of 10 [l of media from
clear wells and incubation for 18 to 24 h (13). The activities
of ciprofloxacin and enoxacin were also determined by agar
dilution with Mueller-Hinton agar (MHA). Inocula were
applied to the surface of MHA containing ciprofloxacin or
enoxacin in 10-p1I drops. The geometric mean log1o (± the
standard deviation) inoculum sizes used in tests on MHA
were 5.9 (±0.4) and 3.9 (±0.4) CFU per spot and 7.2 (±0.4)
and 5.1 (±0.3) CFU/ml in liquid media. Eight clinical isolates
and an American Type Culture Collection control strain of
P. aeruginosa were studied. The strains of Escherichia coli,
Staphylococcus aureus, and Klebsiella pneumoniae studied
each included an American Type Culture Collection control
strain and two clinical isolates. All S. aureus strains were
susceptible to methicillin. All S. aureus were tested in
triplicate, and over 1/3 of other isolates were tested in
duplicate in each medium; the variation was ±1 twofold
dilution (95% confidence interval). The MIC and MBC (log2
*
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Ciprofloxacin and enoxacin were two- to fourfold less active against Pseudomonas aeruginosa in calcium- and
magnesium-supplemented broth compared with unsupplemented broth regardless of inoculum size, presence of
serum, or use of inhibitory or bactericidal endpoints (P < 0.01). The effect of cation supplementation was less
pronounced and less consistent for Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus.
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TABLE 1. Activities of ciprofloxacin and enoxacin in MHB and on MHA and effect of cation supplementation with (MHB-S/HS) or
without (MHB-S) human serum against strains of P. aeruginosa
Media (range) MIC or
(p.gIml) in MHB

Inoculumn size

MIC

and drug

-107 CFU/ml
Ciprofloxacin
Enoxacin

MB

Median fold increase (range) in MIC or MBC (,ug/ml) compared with MHB in:
MHB_Sa

MBC

0.5 (0.125-1)
4 (1-8)

0.25 (0.125-1)
1 (0.5-4)

MHB-S/HSa

MIC

MBC

2 (1-8)
4 (2-4)

4 (2-16)
2 (1-8)

MIC

2 (0.5-4)
4 (1-8)

MHA

MBC

MIC

2 (1-8)
2 (0.25-4)

2 (0.5-8)b
2 (0.5-2)c

-10' CFU/ml
Ciprofloxacin
Enoxacin
b

4 (2-4)
2 (2-4)

4 (1-4)
2 (1-8)

2 (0.5-8)
1 (0.5-4)c

The decrease in activity was statistically significant (P < 0.05) compared with activity in MHB for all comparisons.
The decrease in activity was statistically significant (P < 0.05) compared with activity in MHB.
The decrease in activity was not statistically significant (P > 0.05) compared with activity in MHB.

TABLE 2. In vitro activity of ciprofloxacin (C) and enoxacin (E) against four laboratory reference strains in four media tested at
inoculum sizes of 107 CFU/ml in liquid media and 106 CFU per spot on MHA
MIC (MBC) (j.Lg/ml) with:
Organism

Drug

MHB-S

MHB

MHB-S/HS

MHA

P. aeruginosa ATCC 27853

C
E

0.5 (1)
4 (4)

1 (2)
8 (8)

1 (1)
4 (8)

2
8

E. coli ATCC 25922

C
E

0.008 (0.008)
0.062 (0.062)

0.016 (0.016)
0.125 (0.125)

0.008 (0.008)
0.125 (0.125)

0.016
0.062

K. pneumoniae ATCC 13883

C
E

0.031 (0.031)
0.25 (0.5)

0.062 (0.062)
0.25 (0.5)

0.008 (0.016)
0.125 (0.125)

0.062
0.25

S. aureus ATCC 29213

C
E

0.25 (0.25)
1 (1)

0.5 (0.5)
1 (2)

1 (2)
2 (2)

0.5
1

MBC; data not shown) was only one twofold dilution higher
(range 0 to 3) with the larger inoculum in each of the four
media.
Reduction of antibiotic activity against P. aeruginosa with
magnesium and calcium supplementation has been reported
for various drugs, such as aminoglycosides (10, 16),
polymyxins (6, 12), and ceftazidime (5). The results of the
present study demonstrate that magnesium and calcium
supplementation of MHB also results in statistically significant increases in the MICs and MBCs of two new quinolones
against P. aeruginosa. However, this increase appears to be
lower than that observed with aminoglycosides (10, 16).
It has been shown that the activities of ciprofloxacin and
enoxacin against aerobic gram-positive and gram-negative
bacteria are decreased in urine and at pH <7 (2-4, 14, 15).
Reeves et al. (14) and Ratcliffe and Smith (N. T. Ratcliffe
and J. T. Smith, 4th Mediterranean Congress of Chemotherapy, abstr. no. 608, 1984) have suggested that reduction of
quinolone activity in urine may be due to high urinary
concentrations of magnesium. Our data show that magnesium and calcium concentrations similar to that observed in
serum also may result in alterations in the activities of
ciprofloxacin and enoxacin, particularly against P. aeruginosa. In contrast to the data of Ratcliffe and Smith, we did
not note a disproportionate rise in MIC and MBC in cationsupplemented media.
The presence of serum or a 100-fold increase in inoculum
size had little effect on the in vitro activities of ciprofloxacin
and enoxacin against most major pathogens, which is consistent with previous reports (2, 4, 9, 14, 15).

The reduction of in vitro activity in cation-supplemented
broth may be of consideration in the development of standards for in vitro susceptibility testing of quinolones against
bacteria usually inhibited at or near the susceptibility
breakpoint (e.g., P. aeruginosa). For example, using the
preliminary breakpoint for susceptibility of an MIC c 4
p.g/ml for enoxacin (17), all nine strains of P. aeruginosa
tested with an inoculum of 105 would be considered susceptible in MHB; however, only seven of these strains would be
considered susceptible in MHB-S. In contrast, all strains
would be considered susceptible (1) to ciprofloxacin (MIC <
1 ,ug/ml) in all of the media tested. Further studies correlating the in vitro susceptibility patterns of bacteria in unsupplemented and cation-supplemented media with clinical
results are required to determine the role of medium supplementation in predictions of in vivo efficacy in the treatment of infections due to P. aeruginosa with these new

quinolones.
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